Teitur is a preclinical stage company, developing novel therapeutics for treating neurodegenerative diseases, including Huntington’s Disease, Parkinson’s Disease and Frontotemporal Dementia. The lead program is a cyclic, lipidated peptide, TT-P34, that target the three major pathophysiological hallmarks of neurodegeneration: mitochondrial failure, lysosomal dysfunction, and loss of pro-survival signaling.
Location: Aarhus, Denmark
Sound contact: Casper Breum (Board Director) and Thomas Tan (Board observer)
Web: https://teiturtrophics.com/
Read an interview with Simon Mølgaard Jensen, CEO & Founder The drive to adapt a lab discovery into treatment of neurodegeneration
